Intratumoral microbiota, the diverse community of microorganisms residing within tumor tissues, represent an emerging and intriguing field in cancer biology. These microbial populations are distinct from the well-studied gut microbiota, offering novel insights into tumor biology, cancer progression, and potential therapeutic interventions. Recent studies have explored the use of certain antibiotics to modulate intratumoral microbiota and enhance the efficacy of cancer therapies, showing promising results. Antibiotics can alter intratumoral microbiota’s composition, which may have a major role in promoting cancer progression and immune evasion. Certain bacteria within tumors can promote immunosuppression and resistance to therapies. By targeting these bacteria, antibiotics can help create a more favorable environment for chemotherapy, targeted therapy, and immunotherapy to act effectively. Some bacteria within the tumor microenvironment produce immunosuppressive molecules that inhibit the activity of immune cells. The combination of antibiotics and other cancer therapies holds significant promise for creating a synergistic effect and enhancing the immune response against cancer. In this review, we analyze several preclinical studies that have been conducted to demonstrate the synergy between antibiotics and other cancer therapies and discuss possible clinical implications.
肿瘤内微生物群，即存在于肿瘤组织内的多样化微生物群落，代表了癌症生物学中一个新兴且引人入胜的研究领域。这些微生物群体与已被深入研究的肠道微生物群不同，为肿瘤生物学、癌症进展以及潜在的治疗干预提供了新的见解。近期研究探索了利用特定抗生素调节肿瘤内微生物群以增强癌症疗法疗效的方法，并显示出令人鼓舞的结果。抗生素能够改变肿瘤内微生物群的组成，而后者可能在促进癌症进展和免疫逃逸中发挥重要作用。肿瘤内的某些细菌可促进免疫抑制并导致治疗抵抗。通过靶向这些细菌，抗生素有助于为化疗、靶向治疗和免疫疗法创造更有利的作用环境。肿瘤微环境中的部分细菌会产生抑制免疫细胞活性的免疫抑制分子。抗生素与其他癌症疗法的联合应用，在产生协同效应和增强抗肿瘤免疫反应方面展现出巨大潜力。本文综述分析了多项旨在证明抗生素与其他癌症疗法协同作用的临床前研究，并探讨了其可能的临床意义。
肿瘤(癌症)患者之家